BR112015023404A8 - composições farmacêuticas contendo sequestrantes de precursores de produto final de glicação avançada (age) e uso dos mesmos - Google Patents
composições farmacêuticas contendo sequestrantes de precursores de produto final de glicação avançada (age) e uso dos mesmos Download PDFInfo
- Publication number
- BR112015023404A8 BR112015023404A8 BR112015023404A BR112015023404A BR112015023404A8 BR 112015023404 A8 BR112015023404 A8 BR 112015023404A8 BR 112015023404 A BR112015023404 A BR 112015023404A BR 112015023404 A BR112015023404 A BR 112015023404A BR 112015023404 A8 BR112015023404 A8 BR 112015023404A8
- Authority
- BR
- Brazil
- Prior art keywords
- precursors
- age
- pharmaceutical compositions
- end product
- advanced glycation
- Prior art date
Links
- 239000002243 precursor Substances 0.000 title abstract 8
- 108010005094 Advanced Glycation End Products Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003352 sequestering agent Substances 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 125000004989 dicarbonyl group Chemical group 0.000 abstract 1
- 235000005911 diet Nutrition 0.000 abstract 1
- 230000000378 dietary effect Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
- C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Polymers & Plastics (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792719P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/024436 WO2014150873A1 (en) | 2013-03-15 | 2014-03-12 | Sequestrants of advanced glycation end product (age) precursors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015023404A2 BR112015023404A2 (pt) | 2017-07-18 |
| BR112015023404A8 true BR112015023404A8 (pt) | 2019-12-03 |
Family
ID=50439508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015023404A BR112015023404A8 (pt) | 2013-03-15 | 2014-03-12 | composições farmacêuticas contendo sequestrantes de precursores de produto final de glicação avançada (age) e uso dos mesmos |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20160024233A1 (enExample) |
| EP (1) | EP2968403A1 (enExample) |
| JP (4) | JP2016512830A (enExample) |
| KR (1) | KR20150130492A (enExample) |
| CN (1) | CN105188718A (enExample) |
| AR (1) | AR095593A1 (enExample) |
| AU (2) | AU2014235500A1 (enExample) |
| BR (1) | BR112015023404A8 (enExample) |
| CA (1) | CA2906501A1 (enExample) |
| CL (1) | CL2015002624A1 (enExample) |
| CR (1) | CR20150545A (enExample) |
| DO (1) | DOP2015000221A (enExample) |
| EA (1) | EA201591733A1 (enExample) |
| HK (1) | HK1220607A1 (enExample) |
| IL (1) | IL241406A0 (enExample) |
| MA (1) | MA38487A1 (enExample) |
| MX (1) | MX2015012843A (enExample) |
| PE (1) | PE20151766A1 (enExample) |
| PH (1) | PH12015502019A1 (enExample) |
| SG (2) | SG11201506413PA (enExample) |
| TN (1) | TN2015000390A1 (enExample) |
| TW (1) | TW201521744A (enExample) |
| UY (1) | UY35441A (enExample) |
| WO (1) | WO2014150873A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41202A (fr) * | 2014-12-18 | 2017-10-24 | Genzyme Corp | Copolymères polydiallymine réticulé pour le traitement du diabète de type 2 |
| MX2020002048A (es) * | 2017-08-31 | 2020-09-21 | Cytosorbents Corp | Reduccion de productos finales de glicacion avanzada a partir de fluidos corporales. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985938A (en) * | 1997-11-05 | 1999-11-16 | Geltex Pharmaceuticals, Inc. | Method for reducing oxalate |
| JP4499363B2 (ja) * | 2001-04-18 | 2010-07-07 | ジェンザイム コーポレーション | 血清グルコースの減少方法 |
| WO2005032563A1 (en) * | 2003-09-02 | 2005-04-14 | Genzyme Corporation | Method for reducing vascular inflammation |
| US7385012B2 (en) * | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
| US7459502B2 (en) * | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| EP1753861A4 (en) * | 2004-02-17 | 2010-03-10 | Dynamis Therapeutics Inc | FRUCTOSAMINE-3-KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN |
| FR2883873B1 (fr) * | 2005-03-31 | 2009-07-10 | Pharmamens Sarl | Inhibiteurs d'age |
| US9181364B2 (en) * | 2010-02-24 | 2015-11-10 | Relypsa, Inc. | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants |
-
2014
- 2014-03-12 SG SG11201506413PA patent/SG11201506413PA/en unknown
- 2014-03-12 EP EP14715503.0A patent/EP2968403A1/en not_active Withdrawn
- 2014-03-12 MX MX2015012843A patent/MX2015012843A/es unknown
- 2014-03-12 JP JP2016501535A patent/JP2016512830A/ja active Pending
- 2014-03-12 SG SG10201707590XA patent/SG10201707590XA/en unknown
- 2014-03-12 MA MA38487A patent/MA38487A1/fr unknown
- 2014-03-12 WO PCT/US2014/024436 patent/WO2014150873A1/en not_active Ceased
- 2014-03-12 US US14/776,059 patent/US20160024233A1/en not_active Abandoned
- 2014-03-12 HK HK16108617.8A patent/HK1220607A1/zh unknown
- 2014-03-12 BR BR112015023404A patent/BR112015023404A8/pt not_active Application Discontinuation
- 2014-03-12 PE PE2015001994A patent/PE20151766A1/es unknown
- 2014-03-12 KR KR1020157028860A patent/KR20150130492A/ko not_active Withdrawn
- 2014-03-12 CN CN201480026330.6A patent/CN105188718A/zh active Pending
- 2014-03-12 CA CA2906501A patent/CA2906501A1/en not_active Abandoned
- 2014-03-12 EA EA201591733A patent/EA201591733A1/ru unknown
- 2014-03-12 AU AU2014235500A patent/AU2014235500A1/en not_active Abandoned
- 2014-03-13 TW TW103108910A patent/TW201521744A/zh unknown
- 2014-03-14 UY UY0001035441A patent/UY35441A/es not_active Application Discontinuation
- 2014-03-17 AR ARP140101218A patent/AR095593A1/es unknown
-
2015
- 2015-09-04 TN TN2015000390A patent/TN2015000390A1/en unknown
- 2015-09-08 DO DO2015000221A patent/DOP2015000221A/es unknown
- 2015-09-09 IL IL241406A patent/IL241406A0/en unknown
- 2015-09-09 PH PH12015502019A patent/PH12015502019A1/en unknown
- 2015-09-11 CL CL2015002624A patent/CL2015002624A1/es unknown
- 2015-10-13 CR CR20150545A patent/CR20150545A/es unknown
-
2017
- 2017-12-14 US US15/842,177 patent/US20180265613A1/en not_active Abandoned
-
2018
- 2018-04-25 JP JP2018083623A patent/JP2018135365A/ja active Pending
-
2019
- 2019-02-22 AU AU2019201259A patent/AU2019201259A1/en not_active Abandoned
- 2019-12-06 JP JP2019220818A patent/JP2020055850A/ja active Pending
-
2021
- 2021-12-17 JP JP2021204770A patent/JP2022037143A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022037143A (ja) | 2022-03-08 |
| PE20151766A1 (es) | 2015-12-11 |
| SG10201707590XA (en) | 2017-11-29 |
| HK1220607A1 (zh) | 2017-05-12 |
| MA38487A1 (fr) | 2017-12-29 |
| BR112015023404A2 (pt) | 2017-07-18 |
| AU2019201259A1 (en) | 2019-03-14 |
| JP2020055850A (ja) | 2020-04-09 |
| IL241406A0 (en) | 2015-11-30 |
| CR20150545A (es) | 2015-12-01 |
| MX2015012843A (es) | 2016-08-08 |
| US20160024233A1 (en) | 2016-01-28 |
| EP2968403A1 (en) | 2016-01-20 |
| EA201591733A1 (ru) | 2016-01-29 |
| TN2015000390A1 (en) | 2017-01-03 |
| CA2906501A1 (en) | 2014-09-25 |
| TW201521744A (zh) | 2015-06-16 |
| AU2014235500A1 (en) | 2015-11-05 |
| DOP2015000221A (es) | 2015-12-15 |
| AR095593A1 (es) | 2015-10-28 |
| JP2016512830A (ja) | 2016-05-09 |
| SG11201506413PA (en) | 2015-09-29 |
| CN105188718A (zh) | 2015-12-23 |
| JP2018135365A (ja) | 2018-08-30 |
| WO2014150873A1 (en) | 2014-09-25 |
| KR20150130492A (ko) | 2015-11-23 |
| CL2015002624A1 (es) | 2016-03-11 |
| PH12015502019A1 (en) | 2016-01-11 |
| UY35441A (es) | 2014-10-31 |
| US20180265613A1 (en) | 2018-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201501032A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
| EA201990043A1 (ru) | Антибактериальные соединения | |
| EA201890204A1 (ru) | Антибактериальные соединения | |
| BR112015026830A8 (pt) | composto, composição farmacêutica, combinação, produto, uso de um composto, e, método para profilaxia ou tratamento de um estado de doença ou condição | |
| MX2013003635A (es) | Compuestos de n-heteroarilo. | |
| BR112014010183B8 (pt) | Composto, composição farmacêutica, produto, e, uso de um composto | |
| BR112014029762A2 (pt) | composição contendo n-metil-n-acilglucamina | |
| EA201591166A1 (ru) | Ингибиторы аутотаксина | |
| CL2014002757A1 (es) | Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer. | |
| BR112015008447A2 (pt) | métodos para tratar câncer | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| BR112016007536A8 (pt) | compostos, composições e utilizações correspondentes, para a prevenção e/ou o tratamento de dislipidemias | |
| MA38399B2 (fr) | Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique | |
| EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
| MX374129B (es) | Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos. | |
| BR112018000632A8 (pt) | Moléculas de anticorpo que ligam a cd79 | |
| PH12015502275A1 (en) | Therapuetic uses of empagliflozin | |
| MX375049B (es) | Proteinas especificas novedosas para pioverdina y pioquelina. | |
| MX2019012375A (es) | Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1). | |
| CY1121238T1 (el) | Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων | |
| BR112014032583A2 (pt) | forma farmacêutica para liberação prolongada de substâncias ativas | |
| AU2017261919A1 (en) | Fat and medical uses thereof | |
| CL2015001881A1 (es) | Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición. | |
| BR112015023404A8 (pt) | composições farmacêuticas contendo sequestrantes de precursores de produto final de glicação avançada (age) e uso dos mesmos | |
| BR112015019084A2 (pt) | métodos para aumentar o rendimento das culturas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |